GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotechnology Assets SA (XMAD:BST) » Definitions » Days Sales Outstanding

Biotechnology Assets (XMAD:BST) Days Sales Outstanding : 222.68 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Biotechnology Assets Days Sales Outstanding?

Biotechnology Assets's average Accounts Receivable for the six months ended in Dec. 2023 was €2.65 Mil. Biotechnology Assets's Revenue for the six months ended in Dec. 2023 was €2.17 Mil. Hence, Biotechnology Assets's Days Sales Outstanding for the six months ended in Dec. 2023 was 222.68.

The historical rank and industry rank for Biotechnology Assets's Days Sales Outstanding or its related term are showing as below:

XMAD:BST' s Days Sales Outstanding Range Over the Past 10 Years
Min: 68.08   Med: 294.76   Max: 1711.47
Current: 250.63

During the past 13 years, Biotechnology Assets's highest Days Sales Outstanding was 1711.47. The lowest was 68.08. And the median was 294.76.

XMAD:BST's Days Sales Outstanding is ranked worse than
85.35% of 894 companies
in the Biotechnology industry
Industry Median: 72.38 vs XMAD:BST: 250.63

Biotechnology Assets's Days Sales Outstanding increased from Dec. 2022 (218.64) to Dec. 2023 (222.68).

Biotechnology Assets Days Sales Outstanding Historical Data

The historical data trend for Biotechnology Assets's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotechnology Assets Days Sales Outstanding Chart

Biotechnology Assets Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,711.47 1,164.39 312.71 329.39 264.10

Biotechnology Assets Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 197.52 501.23 218.64 276.17 222.68

Competitive Comparison of Biotechnology Assets's Days Sales Outstanding

For the Biotechnology subindustry, Biotechnology Assets's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotechnology Assets's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotechnology Assets's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Biotechnology Assets's Days Sales Outstanding falls into.


Biotechnology Assets Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Biotechnology Assets's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (2.122 + 3.089) / 2 ) / 3.601*365
=2.6055 / 3.601*365
=264.10

Biotechnology Assets's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (2.209 + 3.089) / 2 ) / 2.171*365 / 2
=2.649 / 2.171*365 / 2
=222.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotechnology Assets  (XMAD:BST) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Biotechnology Assets Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Biotechnology Assets's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotechnology Assets (XMAD:BST) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotechnology Assets SA (XMAD:BST) » Definitions » Days Sales Outstanding
Comparable Companies
XMAD:ORY OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270 BMRN XBRU:UCB RPRX LEGN
Traded in Other Exchanges
N/A
Address
Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Website
https://www.biatgroup.com
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.